Gradient Biomodeling LLC has developed a computational playform for the modeling of biomolecular interactions and pathways. The company's unique algorithms bridge the gap between quantum theory and molecular modeling practice, and allow the application of quantum methods to largeâscale in silico discovery of compounds with therapeutic and other properties of interest. The technology has been applied for drug discovery and design, drug repositioning, small-molecule diagnostics, and biomarker discovery. Gradient has taken a systematic, data-driven approach to both NCE development and drug repositioning, and has developed a portfolio of quantum models for over 1,200 publicly available drug-target datasets.
